Genmab is a biotechnology company that specializes in the discovery and development of differentiated antibody therapeutics for the treatment of cancer. The company has a broad pipeline of innovative product candidates in various stages of development, including both proprietary and partnered products.
Some key highlights of Genmab include:
The company's lead product, Darzalex (daratumumab), is a first-in-class human CD38 monoclonal antibody that has been approved for the treatment of multiple myeloma.
Genmab has a strong partnership with Janssen Biotech, a subsidiary of Johnson & Johnson, for the development and commercialization of Darzalex.
The company's pipeline includes a range of early- to late-stage product candidates targeting various cancers, including hematological malignancies and solid tumors.
Genmab's proprietary pipeline includes several next-generation antibody therapeutics, including bispecific antibodies, antibody-drug conjugates, and immune-modulating agents.
The company has a strong focus on leveraging its world-class antibody expertise to create differentiated and best-in-class therapeutics for the treatment of cancer and other diseases.
Genmab is headquartered in Copenhagen, Denmark, and has operations in the United States and Japan.
|
